Drug profile · INN
nemolizumab
NEMLUVIO
nemolizumab (NEMLUVIO) is a interleukin-31 receptor subunit alpha inhibitor.
EMA: approved PMDA: approved Dermatologicals (D11) D11AH12
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — nemolizumab
- Class
- Dermatologicals (D11)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
nemolizumab (NEMLUVIO) is a interleukin-31 receptor subunit alpha inhibitor.
Key facts
INN nemolizumab
Brand NEMLUVIO
Mechanism Interleukin-31 receptor subunit alpha inhibitor
Target Interleukin-31 receptor subunit alpha
Therapeutic class Dermatologicals (D11)
ATC code D11AH12
Mechanism of action
Interleukin-31 receptor subunit alpha inhibitor
Primary target: Interleukin-31 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nemolizumab?
nemolizumab (NEMLUVIO) is a interleukin-31 receptor subunit alpha inhibitor.
What is the brand name for nemolizumab?
NEMLUVIO is a marketed brand name for nemolizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.